Products
Naratriptan is commercially available in the form of film-coated tablets (Naramig). It has been approved in many countries since 1997.
Structure and properties
Naratriptan (C17H25N3O2S, Mr = 335.5 g/mol) is structurally related to serotonin and is an indole and piperidine derivative. It is present in drugs as naratriptan hydrochloride, a white to slightly yellowish powder that is highly soluble in water.
Effects
Naratriptan (ATC N02CC02) has vasoconstrictive, analgesic, and anti-inflammatory properties. The effects are due to agonism at 5HT1B and 5HT1D serotonin receptors.
Indications
For acute treatment of migraine with or without aura.
Dosage
According to the SmPC. During treatment, the low maximum daily dose (5 mg) and dosing interval (four hours) must be observed. The tablets should be taken as soon as possible after the onset of migraine headache. However, they should not be used as a preventive measure.
Contraindications
- Hypersensitivity
- Certain cardiovascular diseases
- Severe liver or kidney failure
- Basilar migraine
- Hemiplegic and ophthalmoplegic migraine
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are possible with MAO inhibitors and drugs with serotonergic effects (risk of serotonin syndrome).
Adverse effects
The most common possible adverse effects include tingling, pain, sensation of heat, nausea, vomiting, a feeling of pressure, tightness, or heaviness.
